Alexandra Durr on riluzole in patients with spinocerebellar ataxia type 2
The Lancet Neurology in conversation with
English - February 22, 2022 10:00 - 7 minutes - 5.48 MBLife Sciences Science Education stroke alzheimer's epilepsy sleep cerebral multiple sclerosis Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Giuseppe Citerio on frailty and TBI
Next Episode: John Collinge on a treatment for CJD
Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.
Read the full article:
Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL)
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv